1. 1
Teva introduction 2013

2. Established by three young pharmacists, selling drugs in a small store
Starting out at 1901 in Jerusalem

3. More than a century later
We are among the top 10 pharmaceutical companies and a world leader in Generics

4. Our Vision
Being the most indispensable
medicines company for the world,
executing on our obligation to
our patients, customers,
shareholders and employees

5. We have Profound Foundations
45,000
employees
73
manufacturing
sites
111
years in
existence
1,000
molecules
60
countries
73B
tablets and
capsules per
annum
55,000+
SKUs
$5.01
2013 EPS
$20.3B
2013 revenues

6. Core Strengths
Leading
healthcare
provider
Balanced
business
model
Integrated
R&D
Manufacturing
strengths
Partnering
experience
Go-to-market
capabilities
Entrepreneurial
employees and
culture

7. Growth drivers
CNS
Respiratory
High-value generics
NTEs (New therapeutic entity)
MS
PD
Oncology
Respiratory
Women’s Health
Branded generics
High-value generics
OTC (over the counter)
MS
Branded generics
Branded generics
Respiratory
Women’s Health
MS
OTC (over the counter)
MS
Generics
Branded generics

8. A truly global operations network

9. Financial Growth
20132012
20,31420,317Sales $M
5,1985,715Operating Income $M
4,2554,671Net Income $M
* Operating income and net income are non-GAAP results

10. Expansion of wealth and health care access
Rising health care costs
Our World Changes
Aging population
Increasing competition in generics
Shift in disease patterns
Rising bar for product innovation
Complicated, expanding global market

11.  Complexity
 Cost
 Network footprint
 Commodity
The new Teva
Less More
 Globalized
 Valuable pipeline
 Sustainable products
 Patient and customer focus
 Balanced profits
 Shareholder value

12. Teva 2017: a reshaped company
 Sector leadership in all areas
 Sustainable profitable growth
 Present in all major markets
 Consistent shareholder value creation
 Successful alliances
 Rich Pipeline

13. Branded
generics business
R&D capabilities
Impact
healthcare system
Pipeline
of high-value products
Generics: a great future
Global
Sustainable
high-barrier to entry
Rapid growth
Dramatically enhanced
in selected areas

14. Research and development
Develop the most competitive
and focused pipeline
to address unmet patient needs
in a highly differentiated way
to drive the growth of Teva
Life and science intimately connected
… that’s uniquely Teva

15. NTEs
High
value
generics
Focused
specialty
portfolio
NTEs - The Future of Teva R&D
NEW THERAPEUTIC ENTITY
Known molecule that is formulated, delivered, or used in a novel way to
address specific patient needs

16. Specialty medicines: focus and build leadership
CNS
Respiratory
New Therapeutic
Entities (NTEs)
Oncology, Women's
Health, Biologics
Protect and expand MS franchise
Build products and pipeline
Invest in capabilities and pipeline
Continue global expansion
Capitalize on unique Teva interface
of Generics and Specialty
Selectively invest

17. 1717
OTC Business
World’s leading provider
of medicines Portfolio of leading brands
Best-in-class
 Consumer understanding
 Brand-building
 Advertising scale
Strong product development and
production capabilitiesWorld’s leading brand-
builder
+
PGT Consumer Healthcare: JV with P&G leverages value in existing OTC business

18. 18
Our Guiding Values
Our Guiding Values represent an unbreakable chain of behaviors ...
and a process that embodies the very nature of how we operate …
at the heart of Teva.

19. 19
Our Storyline
At the heart of Teva, we believe that:
Individual Integrity drives mutual Respect …
Mutual Respect leads to healthy Collaboration …
Healthy Collaboration powers our pursuit of Excellence …
Our pursuit of Excellence is key to Teva’s ongoing Leadership …
… and ongoing Leadership depends upon our individual Integrity.

20. 20